Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C18H13ClF4N6O |
Molar mass | 440.79 g·mol−1 |
3D model (JSmol) | |
| |
|
JNJ-54175446 is an investigational P2X7 receptor antagonist developed by Janssen Pharmaceuticals. It is hoped that the drug can reduce neuroinflammation and therefore treat psychiatric disorders such as major depressive disorder.[1][2][3][4][5][6]